Antitumor and antimetastatic effect of warfarin and heparins

Hejna, 1999, Inhibition of metastases by anticoagulants, J Natl Cancer Inst, 91, 22, 10.1093/jnci/91.1.22

Smorenburg, 2001, The complex effects on heparins on cancer progression and metastasis in experimental studies, Pharmacol Rev, 53, 93

Li, 2001, Effect of heparin on apoptosis in human nasopharyngeal carcinoma CNE2 cells, Cell Res, 11, 311, 10.1038/sj.cr.7290101

Meyer, 1998, Mechanisms of tumour metastasis, Eur Cancer, 34, 214, 10.1016/S0959-8049(97)10129-0

Zacharski, 1998, Heparin and cancer, Thromb Haemost, 80, 10, 10.1055/s-0037-1615131

Elias, 1975, Heparin and chemotherapy in the management of inoperable lung carcinoma, Cancer, 36, 129, 10.1002/1097-0142(197507)36:1<129::AID-CNCR2820360109>3.0.CO;2-S

Milas, 1985, Treatment with cortisone plus heparin or hexuronyl hexoaminoglycan sulfates of murine tumors and their lung deposits, Clin Exp Metastasis, 3, 247, 10.1007/BF01585080

Maat, 1981, Anticoagulants and experimental metastases—evaluation of antimetastatic effects in different model systems, J Cancer Res Clin Oncol, 101, 275, 10.1007/BF00410113

Wood S, Holyoke ED, Yardley JH. Mechanisms of metastatic production by blood-borne cancer cells. Can Cancer Conf 4:167–223;161.

Lee, 1990, Inhibition of growth and angiogenesis of human neurofibrosarcoma by heparin and hydrocortisone, J Neurosurg, 73, 429, 10.3171/jns.1990.73.3.0429

Lee, 1988, Comparison of metastatic cell lines derived from a murine mammary tumor and reduction of metastasis by heparin, Clin Exp Metastasis, 6, 463, 10.1007/BF01784377

Drago, 1984, The evaluation of heparin in control of metastasis of Nb rat androgen-insensitive prostate carcinoma, Anticancer Res, 4, 171

Tiozzo, 1989, Effect of heparin-like compounds on the in vitro proliferation and protein synthesis of various types cells, Arzneim-Forsch, 39, 15

Au, 1993, Mechanisms of inhibition by heparin of vascular smooth muscle cell proliferation and migration, Haemostasis, 23, 177

Bennet, 1994, Deregulated expression of the c-myc oncogene abolishes inhibition of proliferation of rat vascular smooth muscle cells by serum reduction, interferon-gamma, heparin and cyclic nucleotide analogues and induces apoptosis, Circ Res, 74, 525, 10.1161/01.RES.74.3.525

Lebeau, 1994, Subcutaneous heparin treatment increases survival in small cell lung cancer, Cancer, 74, 38, 10.1002/1097-0142(19940701)74:1<38::AID-CNCR2820740108>3.0.CO;2-E

Aramaki, 1999, Potential role of heparin in prevention of liver metastasis from colon cancer, Hepato Gastroenterol, 46, 3241

Vlodavsky, 1994, Inhibition of tumor metastasis by heparanase inhibiting species of heparin, Invasion Metastasis, 14, 290

Sciumbata, 1996, Treatment with modified heparins inhibits experimental metastasis formation and leads, in some animals, to long-term survival, Invasion Metastasis, 16, 132

Folkman, 1983, Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone, Science, 221, 719, 10.1126/science.6192498

Lapierre, 1996, Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and anti-metastatic properties, Glycobiology, 6, 355, 10.1093/glycob/6.3.355

McCulloch, 1989, Warfarin inhibits metastasis of Mtln3 rat mammary carcinoma without affecting primary tumour growth, Br J Cancer, 59, 179, 10.1038/bjc.1989.37

McCulloch, 1987, Warfarin inhibition of metastasis: the role of anticoagulation, Br J Surg, 74, 879, 10.1002/bjs.1800741005

Folkmann, 1997, Angoiogenesis and angiogenesis inhibition: an overview, EXS, 79, 1

Norrby, 1993, Heparin and angiogenesis: a low-molecular-weight fraction inhibits and a high-molecular-weight fraction stimulates angiogenesis systemically, Haemostasis, 23, 141

Norrby, 1996, Basic-fibroblast-growth-factor-mediated de novo angiogenesis is more effectively suppressed by low-molecular-weight than by high-molecular-weight heparin, Int J Microcirc Clin Exp, 16, 8, 10.1159/000179145

Jayson, 1997, Heparin oligosaccharides: inhibitors of the biological activity of bFGF on Caco-2 ells, Br J Cancer, 75, 9, 10.1038/bjc.1997.3

Soker, 1994, Variation in the size and sulfation of heparin modulate the effect of heparin on the binding of VEGF 165 to its receptors, Biochem Biophys Res Commun, 203, 1339, 10.1006/bbrc.1994.2329

Lepri, 1994, J Ocul Pharmacol, 10, 273, 10.1089/jop.1994.10.273

Constantini, 1992, The role of fibrin in tumor metastasis, Cancer Metastasis Rev, 11, 283, 10.1007/BF01307183

Dvorak, 1987, Fibrin containing gels induce angiogenesis. Implication for tumor stroma generation and wound healing, Lab Invest, 57, 673

Collen, 1998, The influence of fibrin structure on the formation and maintenance of capillary-like tubules, Angiogenesis, 2, 153, 10.1023/A:1009240522808

Parise, 1993, Effects of low molecular weight heparins on fibrin polymerization and clot sensitivity to t-PA-induce lysis, Blood Coagul Fibrinolysis, 4, 721, 10.1097/00001721-199310000-00008

Collen, 2000, Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro, Cancer Res, 60, 6196

Novotny, 1991, Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples, Blood, 78, 387, 10.1182/blood.V78.2.387.387

Pepe, 1997, Tissue factor and plasminogen activator inhibitor type 2 expression in human stimulated monocytes is inhibited by heparin, Semin Thromb Hemostasis, 23, 135, 10.1055/s-2007-996081

Ruf, 1996, Tissue factor in cancer angiogenesis and metastasis, Curr Opin Hematol, 3, 379, 10.1097/00062752-199603050-00008

Poon, 2001, Clinical implications of circulating angiogenic factors in cancer patients, J Clin Oncol, 19, 1207, 10.1200/JCO.2001.19.4.1207

Kakkar, 1999, Role of tissue factor expression on tumor cell invasion and growth of experimental pancreatic adenocarcinoma, Br J Surg, 86, 890, 10.1046/j.1365-2168.1999.01153.x

Zhang, 1994, Tissue factors controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice, J Clin Invest, 94, 1320, 10.1172/JCI117451

Bromberg, 1999, Role of tissue factor in metastasis: functions of the cytoplasmatic and extracellular domains if the molecule, Thromb Haemostasis, 82, 88, 10.1055/s-0037-1614634

Abe, 1999, Regulation of vascular endothelial growth factor production and angiogenesis by cytoplasmatic tail of tissue factor, Proc Natl Acad Sci USA, 96, 8663, 10.1073/pnas.96.15.8663

Mousa, 2002, Anticoagulants in thrombosis and cancer: the missing link, Semin Thromb Hemost, 28, 45, 10.1055/s-2002-20559

Hilgard, 1981, The use of oral anticoagulant in tumor therapy, 103

Maat, 1980, Selective macrophage inhibition abolishes warfarin-induced reduction of metastasis, Br J Cancer, 41, 313, 10.1038/bjc.1980.46

Gorelik, 1982, Role of NK cells in the control of metastatic spread and growth of tumor cells in mice, Int J Cancer, 30, 107, 10.1002/ijc.2910300118

Gorelik, 1984, Role of NK cells in the antimetastatic effect of anticoagulant drugs, Int J Cancer, 33, 87, 10.1002/ijc.2910330115

Gorelik, 1987, Augmentation of the antimetastatic effect of anticoagulant drugs by immunostimulation in mice, Cancer Res, 47, 809

Ostensen, 1987, Tumor necrosis factor enhances cytolytic activity of human natural killer cells, J Immunol, 138, 4185, 10.4049/jimmunol.138.12.4185

Ortaldo, 1987, Regulation of natural killer activity, Cancer Metastasis Rev, 637, 10.1007/BF00047471

Sylvester, 1990, Augmentation of antimetastatic activity of interferon and tumor necrosis factor by heparin, Immunopharmacol Immunotoxicol, 12, 161, 10.3109/08923979009019667

Itoh, 1995, Heparin effects on superoxide production by neutrophils, Eur Surg Res, 27, 184, 10.1159/000129398

Leculier, 1993, The effects of high molecular weight and low molecular weight heparins on superoxide ion production and degranulation by human polymorphonuclear leukocytes, Thromb Res, 69, 519, 10.1016/0049-3848(93)90056-T

Handa, 1991, Selectin GMP-140 (D62; PADGEM) binds to sialosyl-Le(a) and sialosyl-Le(x), and sulfated glycans modulate this binding, 181, 1223

Nelson, 1993, Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation, Blood, 82, 3253, 10.1182/blood.V82.11.3253.3253

Koenig, 1998, Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractioned and low molecular weight heparins as therapeutic agents, J Clin Invest, 101, 877, 10.1172/JCI1509

Atanahopoulos, 1995, In vitro effects of heparin on SW480 tumor cell matrix interaction, Anticancer Res, 15, 1411

Saiki, 1990, Inhibition by sulfated chitin derivatives of invasion through extracellular matrix and enzymatic degradation by metastatic melanoma cells, Cancer Res, 50, 3631

McCarthy, 1990, RGD-independent cell adhesion to the carboxy-terminal heparin-binding fragment of fibronectin involves heparin-dependent and -independent activities, J Cell Biol, 110, 777, 10.1083/jcb.110.3.777

Liang, 1997, Identification of novel heparin-binding domains of vibronectin, FEBS Lett, 407, 169, 10.1016/S0014-5793(97)00330-X

Othaka, 1996, Role of extracellular matrix on colonic cancer cell migration and proliferation, Biochem Biophys Res Commun, 220, 346, 10.1006/bbrc.1996.0408

Nakajima, 1988, Heparanases and tumor metastasis, J Cell Biochem, 36, 157, 10.1002/jcb.240360207

Eccles, 1999, Heparanase: breaking down barriers in tumors, Nat Med, 5, 735, 10.1038/10455

Lersch, 1996, Efficacy of low-molecular-weight heparin and unfractioned heparin to prevent adhesion of human prostate and bladder carcinoma and melanoma cells to bovine endothelial monolayers, Urol Int, 56, 230, 10.1159/000282848

Bobek, 2003, Inhibition of adhesion breast cancer cells by anticoagulant drugs and cimetidine, Neoplasma, 50, 148

Nakagoe, 2001, Circulating sialyl LewisX, sialyl LewisA, and sialyl Tn antigens in colorectal cancer patients: multivariate analysis of predictive factors for serum antigen levels, J Gastroenterol, 36, 166, 10.1007/s005350170124

Srinivas, 1996, E-selectin: sialyl Lewis, a dependent adhesion of colon cancer cells, is inhibited differently by antibodies against E-selectin ligands, Scand J Immunol, 44, 197, 10.1046/j.1365-3083.1996.d01-302.x

Berg, 1991, A carbohydrate domain common to both sialyl-Lex is recognised by the endothelial cell leukocyte adhesion molecule ELAM-1, J Biol Chem, 266, 14869, 10.1016/S0021-9258(18)98555-8

Satoh, 1997, Serum sialyl Lewis X-i antigen levels in non-small cell lung cancer: correlation with distant metastasis and survival, Clin Cancer Res, 3, 495

Grabowski, 2000, Expression of sialyl- LeX antigen defined by Mab-3 is an independent prognostic marker in colorectal carcinoma patients, Int J Cancer, 88, 281, 10.1002/1097-0215(20001015)88:2<281::AID-IJC21>3.0.CO;2-2

Yamaguchi, 1998, Expression of nm23-H1 gene and sialyl Lewis X antigen in breast cancer, Oncology, 55, 357, 10.1159/000011878

Dennis, 1987, Tumor cell surface carbohydrate and the metastatic phenotype, Cancer Metastasis Rev, 5, 185, 10.1007/BF00046998

Hakomori, 1996, Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism, Cancer Res, 56, 5309

Kim, 1997, Perspectives on the significance of altered glycosylation of glycoproteins in cancer, Glycoconjugate J, 14, 569, 10.1023/A:1018580324971

Takada, 1993, Contribution of carbohydrate antigens sialyl Lewis A and sialyl Lewis X to adhesion of human cancer cells to vascular endothelium, Cancer Res, 53, 354

Varki, 1994, Selectin ligands, Proc Natl Acad Sci USA, 91, 7390, 10.1073/pnas.91.16.7390

Kansas, 1996, Selectins and their ligands: current concepts and controversies, Blood, 88, 3259, 10.1182/blood.V88.9.3259.bloodjournal8893259

Varki, 2001, P-selectin, carcinoma metastasis and heparin: novel mechanistic connections with therapeutic implications, Braz J Med Biol Res, 34, 711, 10.1590/S0100-879X2001000600003

Koenig, 1998, Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents, J Clin Invest, 101, 877, 10.1172/JCI1509

Nieswandt, 1999, Lysis of tumor cells by natural killer cells in mice is impeded by platelets, Cancer Res, 59, 1295

Tang, 1994, Adhesion molecules and tumor metastasis: an update, Invasion Metastasis, 14, 109

Amirkhosravi, 2003, Antimetastatic effect of tinzaparin, a low-molecular-weight heparin, J Thromb Haemost, 1, 1972, 10.1046/j.1538-7836.2003.00341.x

Amirkhosravi, 1999, Blockade of GpIIb/IIIa inhibits release of vascular endothelial growth factor (VEGF) from tumor cell-activated platelets and experimental metastasis, Platelets, 10, 285, 10.1080/09537109975915

Mohle, 1997, Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets, Proc Natl Acad Sci USA, 94, 663, 10.1073/pnas.94.2.663

Maloney, 1995, In vitro release of vascular endothelial growth factor during platelet aggregation, Am J Physiol, 275, H1054

Verheul, 2000, Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets, Blood, 96, 4216, 10.1182/blood.V96.13.4216

Trikha, 2002, Multiple roles for platelet GPIIb/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis, Cancer Res, 62, 2824

Prandoni, 1999, Cancer and venous thromboembolism: an overview, Haematologica, 84, 437

Zacharski, 1984, Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate, Cancer, 53, 2046, 10.1002/1097-0142(19840515)53:10<2046::AID-CNCR2820531007>3.0.CO;2-F

Prandoni, 1992, Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis, Lancet, 339, 441, 10.1016/0140-6736(92)91054-C

Hull, 1992, Subcutaneous low molecular-weight heparin compared with intravenous heparin in the treatment of proximal-vein thrombosis, New Engl J Med, 326, 975, 10.1056/NEJM199204093261502

Prandoni, 1997, Venous thromboembolism and cancer: a two-way clinical association, Front Biosci, 2, e12, 10.2741/A221

Kakkar, 1995, Preoperative heparin therapy inhibits late death from metastatic cancer, Int J Oncol, 6, 885

Kohanna, 1983, Effect of preoperative low-dose heparin administration on the course of colon cancer, Surgery, 93, 433

Wojtukiewicz, 2003, Low molecular weight heparin treatment for malignant melanoma: a pilot clinical trial, Thromb Haemost, 89, 405, 10.1055/s-0037-1613458

von Tempelhoff, 2000, Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: a prospective randomized double-blind trial, Int J Oncol, 16, 815